Navigation Links
Treatment With VP20621 (Non-Toxigenic Clostridium difficile; NTCD) In A Phase 2 Study Resulted In High Rates Of Colonization And Statistically Significant Reductions In Recurrence Of C. difficile Infection
Date:4/22/2013

nd fractured a hip; death was attributed to renal failure and pulmonary sepsis.

"I am thrilled by the data from this Phase 2 study of VP20621, which confirm the therapeutic potential of non-toxigenic C. difficile," commented Dale Gerding , MD, Professor of Medicine at Loyola University Chicago Stritch School of Medicine and research physician at the Hines VA Hospital. "For the first time, we have been able to mimic the protective effect we have inferred from observing natural colonization of patients with non-toxigenic strains of C. difficile. As a clinician on the front lines of CDI research, I find these data to be extremely promising and suggestive of a novel approach to prevention of not only disease recurrence, but primary CDI as well."

Next steps
ViroPharma will complete the evaluation of these Phase 2 data which will help determine a future development pathway. The company reminds its investors that VP20621 was flagged as a non core asset at its September investor event. With these compelling Phase 2 clinical results, we will seek a partner to complete the development and commercialization of the asset.

About VP20621
Antibiotics including those used to treat acute C. difficile infection (CDI) disrupt the normal gastrointestinal flora which renders individuals susceptible to C. difficile colonization. Orally-dosed liquid VP20621 utilizes non-toxigenic spore-based technology as a potential means of recolonization and protection. The goal of VP20621 dosing following antibiotic exposure is to colonize with this non-toxigenic strain of C. difficile and to prevent colonization by toxigenic strains, thereby preventing disease. VP20621 may have therapeutic utility in the prevention of recurrence following treatment of acute CDI and in the primary prevention of CDI. ViroPharma acquired VP20621 in 2006, through a licensing agreement with Dr.
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Following a bipartisan vote in the House ... the Medicare DMEPOS Competitive Bidding Improvement Act of ... released a statement praising the Committee,s work and ... "Today,s mark-up of the Competitive Bidding ... Committee is a critical step forward for this ...
(Date:2/27/2015)... Canada and HOUSTON, TX ... or the "Company") (TSX-V: EPI) and Bloom Burton & ... released from voluntary contractual lock-up (the "Lock-Up") 2,353,130 common ... the Common Shares originally subject to the Lock-Up. Of ... will be free trading immediately upon release from the ...
(Date:2/27/2015)... --  Synageva BioPharma Corp. (Synageva) (NASDAQ: ... products for rare diseases, joins the National Organization ... Rare Diseases™ (EURORDIS™), The Global Genes Project™, and ... Day. On the last day of ... participants conduct special events to raise awareness and ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... one of the nation,s top 25 independent healthcare communications ... national launch of the company,s newly approved Fluoxetine Tablets ... Prozac®   marketed in the U.S.  Fluoxetine is ... major depression, with more than 23 million prescriptions written ...
... CLEVELAND, Nov. 30, 2011 CardioInsight Technologies Inc., ... announced today CE Mark clearance and the European ... to aid in the diagnosis of cardiac arrhythmias. ... that it has secured its first three clinical ...
Cached Medicine Technology:HCB Health Wins Fluoxetine Launch Assignment From Edgemont Pharmaceuticals 2CardioInsight Announces CE Mark Clearance and European Launch of the ECVUE™ Non-Invasive Electrocardiographic Mapping System 2
(Date:2/28/2015)... The Heart Fit Clinic started doing External ... machine. The Heart Fit Clinic is also selling the ... model. The goal is to scale the business to ... buy External Counterpulsation machines can be difficult ... this process and achieve the desired results. , ...
(Date:2/28/2015)... Indosoft Inc , developers of Q-Suite, a ... to announce the development of Q-Suite 5.9. Building off ... Q-Suite, this new version will include enhancements to existing ... to the leading edge call center software. General availability ... features to enhance security and protection. Administrators will be ...
(Date:2/28/2015)... St. Louis, MO (PRWEB) February 28, 2015 ... a leading provider of outsourced sales, marketing and ... announces their client, BIOTA Botanicals, is bringing its ... , Celebrated worldwide, BIOTA Botanicals’ products are specifically ... the herbal care experts, BIOTA is committed to ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 How ... Supportive? Strategic? , There are all kinds of ... To raise awareness of the advantages and applications ... PeopleKeys is launching a new product this spring ... better understand the connection between personality type, leadership, ...
(Date:2/28/2015)... 2015 Javon Bea Mercy Health ... Hospital as stroke capable by the State of Illinois, ... to Mercy Harvard Hospital. , The hospital was required ... ability to treat stroke according to national standards of ... stroke patients to bypass hospitals not designated as an ...
Breaking Medicine News(10 mins):Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2
... VAXINE Pty Ltd, a South Australian biotechnology company, has ... swine flu vaccine. , , ... administration to human subjects of a swine flu vaccine anywhere ... "The swine influenza vaccine we are testing, unlike old-fashioned egg-based ...
... HILLS, Mass., July 22 Joseph F. Finn, Jr., C.P.A. ... have been assigned to him for the benefit of EPIX,s ... and services focus on the discovery and development of novel ... in silico drug discovery platform. The company ...
... DOYLESTOWN, Pa., July 22 Quigley Pharma Inc., a wholly-owned ... www.quigleyco.com , today announced the ... compound QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. ... with the final and comprehensive conclusions revealing that (i) the ...
... , , , ... Inc. (OTC Bulletin Board: TCSR), which develops, manages and owns ... six-month extension of its construction/mini-perm loan with Trustmark National Bank. ... senior living facility in Port Lavaca, Texas, Trustmark National ...
... nutrition expert says, , WEDNESDAY, July 22 (HealthDay News) -- ... the kind of snack that matters, but who eats it. ... non-obese women, the healthy-weight women wanted less of the treat ... and non-obese women respond to high-energy, high-density snacks in different ...
... , , ... of the world,s leading research and advisory firms focusing on ... Bristol-Myers Squibb,s Orencia is low among rheumatoid arthritis agents. Rheumatologists ... necrosis factor-alpha (TNF-alpha) inhibitors across the top drivers of perception ...
Cached Medicine News:Health News:Vaxine Wins Line Honours With World's First Human Swine Flu Vaccine 2Health News:EPIX Pharmaceuticals, Inc. Assigns all Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors 2Health News:Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study 2Health News:Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study 3Health News:Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study 4Health News:Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study 5Health News:TrinityCare Senior Living Announces Extension of Financing for Trinity Shores Facility in Port Lavaca, Texas 2Health News:TrinityCare Senior Living Announces Extension of Financing for Trinity Shores Facility in Port Lavaca, Texas 3Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 2Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 3Health News:For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia 2Health News:For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia 3
FREEDOM® Memory Thumb Spica lets you make a custom splint in minutes. Immerese in 160 F water until pliable, and remove. Amazingly, it maintains its shape and is ready to be precisely, profession...
... Freedom® CMC ThumbFit™ reduces joint instability ... splint is remarkably comfortable and easy ... Kirby, OTR/L, CHT and Robert V. ... splint together in response to patients' ...
... offers thumb and wrist control in a ... Lightweight stays provide firm control at the ... contoured for proper positioning and fit. Ideal ... CMC joint arthritis, and following cast removal. ...
... Soft, foam-lined FoamWrap ThumWrap Splints offer support ... Ideal to relieve mild pain or strain ... activities. Choose either the rigid or the ... amount of support. Washable and breathable, the ...
Medicine Products: